VVY

Vivoryon Therapeut (VVY)

Vivoryon Therapeut

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:EU:VVY

1 2 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/08	14 : 00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024	EU:VVY	Vivoryon Therapeut
2024/04/24	14 : 00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates	EU:VVY	Vivoryon Therapeut
2024/04/16	14 : 00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024	EU:VVY	Vivoryon Therapeut
2024/03/15	15 : 00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Announces Changes to Board Composition	EU:VVY	Vivoryon Therapeut
2024/03/04	15 : 00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease	EU:VVY	Vivoryon Therapeut
2024/01/08	15 : 00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024	EU:VVY	Vivoryon Therapeut
2023/12/06	15 : 00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress	EU:VVY	Vivoryon Therapeut
2023/11/28	15 : 00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023	EU:VVY	Vivoryon Therapeut
2023/11/07	15 : 00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference	EU:VVY	Vivoryon Therapeut
2023/11/07	15 : 00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference	EU:VVY	Vivoryon Therapeut
2023/10/26	14 : 00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision	EU:VVY	Vivoryon Therapeut
2023/10/23	14 : 00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose	EU:VVY	Vivoryon Therapeut
2023/10/23	14 : 00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose	EU:VVY	Vivoryon Therapeut
2023/10/17	22 : 32	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders	EU:VVY	Vivoryon Therapeut
2023/10/17	22 : 32	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders	EU:VVY	Vivoryon Therapeut
2023/10/05	14 : 00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference Participation	EU:VVY	Vivoryon Therapeut
2023/10/05	14 : 00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference Participation	EU:VVY	Vivoryon Therapeut
2023/09/15	20 : 57	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Extraordinary General Meeting Approved Appointment of New Executive Directors to the Board	EU:VVY	Vivoryon Therapeut
2023/09/07	14 : 00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational Progress	EU:VVY	Vivoryon Therapeut
2023/08/31	14 : 00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023	EU:VVY	Vivoryon Therapeut
2023/08/05	06 : 35	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023	EU:VVY	Vivoryon Therapeut
2023/08/05	06 : 30	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer	EU:VVY	Vivoryon Therapeut
2023/07/16	16 : 00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease	EU:VVY	Vivoryon Therapeut
2023/06/22	01 : 02	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting	EU:VVY	Vivoryon Therapeut
2023/06/16	00 : 49	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Announces CEO Transition Plan	EU:VVY	Vivoryon Therapeut
2023/06/01	14 : 00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences	EU:VVY	Vivoryon Therapeut
2023/05/26	14 : 39	GlobeNewswire Inc.	Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million	EU:VVY	Vivoryon Therapeut
2023/05/26	00 : 50	GlobeNewswire Inc.	Vivoryon Therapeutics Launches Capital Increase by Way of an Accelerated Bookbuild Offering	EU:VVY	Vivoryon Therapeut
2023/05/16	14 : 00	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress	EU:VVY	Vivoryon Therapeut
2023/05/09	14 : 02	GlobeNewswire Inc.	Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting on June 21, 2023	EU:VVY	Vivoryon Therapeut